Efficacy and safety of Eribulin as the first line therapy for advanced or recurrent breast cancer patients without HER2 overexpression.

Phase 2

• Conditions: Advanced or metastatic breast cancer

• Registration Number: JPRN-UMIN000006086
• Lead Sponsor: Dept. Surgical Oncology, Osaka City University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-31
• Study Completion: 2015-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

1)having systemic infection 2)pleural effusion,ascites,hydropericardium that is not good control 3)symptomatic brain metastasis 4)patient with following serious complication heart disease that is not good control myocardial infarction in the latest 6th months cirrhosis interstitial pneumonia,pulmonary fibrosis bleeding tendency 5)having active multiple cancers 6)menopausal women patients having possibility pregnancy 7)systemic steroid therapy 8)widespread radiation therapy 9)patient who reject supportive therapy for myelosuppresion 10)judged by the investigator to be unfit to be enrolled into the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified